What are rapamycin's side effects?

It depends enormously on dose. At the high, continuous doses used for decades to prevent transplant rejection, rapamycin (sirolimus) causes well-documented issues: mouth ulcers, elevated blood lipids, delayed wound healing, and insulin resistance, which mouse work links mainly to chronic mTORC2 suppression. At the much lower, often intermittent doses tested in recent aging trials, the picture looks different: the Atlas's own human studies report the drug as well tolerated, with only minor adverse events.

The mechanism behind the metabolic side effects

• SAR2006 M – chronic rapamycin dosing eventually suppresses mTORC2 signaling too, not just mTORC1 – and mTORC2 is what phosphorylates Akt/PKB, a key node in insulin signaling. This is the leading mechanistic explanation, from cell and mouse work (see also LAM2012), for rapamycin-associated insulin resistance: a consequence of chronic exposure, not of the effect the drug is used for.

What the Atlas's low-dose human trials actually report

• KRA2018 H – a safety-first pilot RCT (n=25, ages 70–95) asking the basic tolerability question before any longevity trial: daily rapamycin over 8+ weeks was well tolerated, with only minor adverse events.
• MAN2018 H – a low-dose, selective mTORC1-inhibiting combination in 264 elderly people improved immune function – the opposite direction of "more immunosuppression", showing dose and selectivity change the safety picture, not just the benefit.
• GIL2026 H – in an uncontrolled pilot with no placebo group, people with ME/CFS taking low-dose rapamycin reported less fatigue; the mechanistic links were shown in lab assays, not in patients. A tolerability signal, not evidence of benefit.
• MOE2025 H – a 48-week RCT (n=114) at an aging-relevant dose found no significant change in its primary endpoint – a null efficacy result, but also no signal of the adverse effects associated with chronic high-dose use.

Not every mTOR-inhibitor trial succeeds, or is side-effect free

• MAN2021 H – the crucial reality check: the large phase 3 trial (n=1024) of RTB101, an ATP-competitive inhibitor of PI3K and mTOR rather than a rapalog, failed its primary endpoint for reducing symptomatic respiratory illness. Dose-sparing strategies do not automatically preserve efficacy.

Why the dose distinction matters

Nearly everything people cite as "rapamycin's side effects" – mouth sores, hyperlipidemia, poor wound healing – comes from the transplant-immunosuppression literature, where the drug is dosed continuously and at levels that fully occupy mTORC1 (and, over time, mTORC2). The aging-research community's central bet is that much lower, often intermittent dosing keeps enough benefit while avoiding that profile – a bet the Atlas's open question on mTORC1-selective, mTORC2-sparing dosing and pulsed dosing track directly.

Related entities

Open in the Atlas explorer